ESR1 and neoplasm: CB-103/fulvestrant combination treatment in vivo caused tumor regression and was superior to either agent alone in an ESR1-Y537S mutant model, while CB103 monotherapy or the doublet combination had comparable efficacy to fulvestrant alone in an ESR1 wild-type model.